23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Bio-Rad Laboratories, Inc. › 2025-2026

Bio-Rad Laboratories, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 24, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 456Asset managers, any item
  • 2,975Fund votes
  • April 21, 2026Meeting date

Results at a glance

Meeting of April 21, 2026: 10 items on Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 24, 2026: 3 approved · 6 passed (calculated) · 1 not approved.

Dissent

Notable dissent: 1 shareholder proposal (21.2% support); 2 directors (11.7%, 11.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Bio-Rad Laboratories, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Bio-Rad Laboratories, Inc.

These tallies are Bio-Rad Laboratories, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 24, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Bio-Rad Laboratories, Inc. — official shareholder meeting results, meeting held April 21, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Melinda Litherland 17,316,5232,297,02928,202 --1,351,946 88%Passed (calculated)—
Elect Director: Arnold A. Pinkston 17,423,4682,192,57425,712 --1,351,946 89%Passed (calculated)—
Elect Director: Jeffrey L. Edwards 4,991,11934693 --31,874 99.9%Passed (calculated)—
Elect Director: Gregory K. Hinckley 4,991,07539093 --31,874 99.9%Passed (calculated)—
Elect Director: Allison Schwartz 4,991,15231393 --31,874 99.9%Passed (calculated)—
Elect Director: Norman Schwartz 4,990,99547093 --31,874 99.9%Passed (calculated)—
2. Proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026 7,037,19938,99446,609 ---- 99.4%Approveda majority of the shares outstanding
3. Non-binding advisory vote to approve executive compensation 6,682,605268,1734,956 --167,069 96%Approveda majority of the shares outstanding
4. Proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan 6,847,541105,2432,949 --167,069 98%Approveda majority of the shares outstanding
5. Stockholder proposal regarding dual class capital structure 1,469,2975,459,5546,903 --187,048 21%Not approveda majority of the shares outstanding

Source: Bio-Rad Laboratories, Inc., Form 8-K, filed with the SEC on April 24, 2026 — read the filing on EDGAR.

How asset managers voted at the Bio-Rad Laboratories, Inc. 2025-2026 meeting

456 asset managers disclosed a vote on at least one Bio-Rad Laboratories, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Arnold A. Pinkston

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 17,423,468AGAINST: 2,192,574

Prior year: 82.5% for (April 22, 2025 meeting) ▲ 6.3 pts

Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: Nominees: Arnold A. Pinkston

Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Arnold A. Pinkston”): 17,423,468 for, 2,192,574 against, per its Form 8-K filed April 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 7,705,174 for, 828,809 against, 2,872 abstained, 14 not voted.

FOR
FOR: 7,705,174AGAINST: 828,809ABSTAIN: 2,872NOT VOTED: 14
Largest asset managers voting on “Nominees: Arnold A. Pinkston” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,644,196806 00For
Capital Group764,0420 00For
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST388,1910 00For
Dimensional347,6670 00For
Fidelity35,004274,678 00Mixed
MFS288,7100 00For
Investment Managers Series Trust III259,1060 00For
Parnassus0253,239 00Against
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,78031 00For
John Hancock133,4081,737 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price080,749 00Against
Putnam080,552 00Against
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable26,49020,614 00Mixed
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS038,293 00Against
Jackson National36,6550 00For
FRANKLIN VALUE INVESTORS TRUST034,773 00Against
TIAA26,3270 00For

Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).

Elect Director: Melinda Litherland

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 17,316,523AGAINST: 2,297,029

Prior year: 81.0% for (April 22, 2025 meeting) ▲ 7.3 pts

Details: description as filed, official tally, votes by 117 asset managers

Description as filed by funds: Nominees: Melinda Litherland

Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Melinda Litherland”): 17,316,523 for, 2,297,029 against, per its Form 8-K filed April 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 117 asset managers below reported 7,704,826 for, 829,157 against, 2,872 abstained, 14 not voted.

FOR
FOR: 7,704,826AGAINST: 829,157ABSTAIN: 2,872NOT VOTED: 14
Largest asset managers voting on “Nominees: Melinda Litherland” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,644,196806 00For
Capital Group764,0420 00For
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST388,1910 00For
Dimensional347,6670 00For
Fidelity35,004274,678 00Mixed
MFS288,7100 00For
Investment Managers Series Trust III259,1060 00For
Parnassus0253,239 00Against
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,78031 00For
John Hancock133,4081,737 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price080,749 00Against
Putnam080,552 00Against
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable26,49020,614 00Mixed
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS038,293 00Against
Jackson National36,6550 00For
FRANKLIN VALUE INVESTORS TRUST034,773 00Against
TIAA26,3270 00For

Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).

Proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 6,847,541AGAINST: 105,243
Details: description as filed, official tally, votes by 120 asset managers

Description as filed by funds: Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.

Bio-Rad Laboratories, Inc.’s own tally for this item (“4. The proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan”): 6,847,541 for, 105,243 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes | Broker For | Against | Abstaining | Non-V…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Also reported under other wordings, matched to the same row of Bio-Rad Laboratories, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (4 managers, 16,362 for).

Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR
Largest asset managers voting on “Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,645,0011 00For
Capital Group764,0420 00For
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST388,1910 00For
Dimensional347,6670 00For
Fidelity309,6820 00For
MFS288,7100 00For
Investment Managers Series Trust III259,1060 00For
Parnassus253,2390 00For
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,8110 00For
John Hancock135,1450 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price80,7490 00For
Putnam80,5520 00For
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable47,1040 00For
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS38,2930 00For
Jackson National36,6550 00For
FRANKLIN VALUE INVESTORS TRUST34,7730 00For
TIAA26,3270 00For

Showing the 25 largest of 120 asset managers. All 120 are in the interactive database (link above).

Non-binding advisory vote to approve executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 6,682,605AGAINST: 268,173
Details: description as filed, official tally, votes by 447 asset managers

Description as filed by funds: Advisory vote to approve executive compensation.

Bio-Rad Laboratories, Inc.’s own tally for this item (“3. The non-binding advisory vote to approve executive compensation”): 6,682,605 for, 268,173 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The non-binding advisory vote to approve executive compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes | Broker For | Against | Abstaining | Non-Votes 6,682,605 | 268,173 …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Also reported under other wordings, matched to the same row of Bio-Rad Laboratories, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (10 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 113 asset managers voting on “Advisory vote to approve executive compensation.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,645,0001 00For
Capital Group0764,042 00Against
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST388,1910 00For
Dimensional347,6670 00For
Fidelity309,493189 00For
MFS288,7100 00For
Investment Managers Series Trust III259,1060 00For
Parnassus253,2390 00For
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,8110 00For
John Hancock135,1450 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price80,7490 00For
Putnam80,5520 00For
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable47,1040 00For
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS038,293 00Against
Jackson National6,01030,645 00Mixed
FRANKLIN VALUE INVESTORS TRUST34,7730 00For
TIAA26,3270 00For

No total is shown for the fund voting reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 363 asset managers voting on “Advisory vote to approve executive compensation.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
First Eagle Investment Management, LLC2,360,5530 00For
BlackRock516,896951 00For
EARNEST PARTNERS LLC163,973329,131 00Mixed
MASSACHUSETTS FINANCIAL SERVICES CO /MA/456,5030 00For
Capital Group1450,000 00Against
First Pacific Advisors, LP400,7890 00For
State Street392,8394,805 00For
UBS0342,918 00Against
GEODE CAPITAL MANAGEMENT, LLC340,4650 00For
Capital Research Global Investors0314,042 00Against
Parnassus253,2390 00For
ARIEL INVESTMENTS, LLC244,3430 00For
Mawer Investment Management Ltd.0201,944 00Against
Charles Schwab183,7730 00For
Northern Trust174,203632 00For
DEERFIELD MANAGEMENT COMPANY, L.P.170,6020 00For
GW&K Investment Management, LLC169,5370 00For
THOMPSON SIEGEL & WALMSLEY LLC167,6020 00For
Vanguard142,1960 00For
John Hancock127,6620 00For
T. Rowe Price127,6140 00For
ACADIAN ASSET MANAGEMENT LLC125,9690 00For
MELLON INVESTMENTS Corp56123,732 00Against
Putnam115,2020 00For
Allspring109,3040 00For

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 7,037,199AGAINST: 38,994

Prior year: 99.3% for (April 22, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.

Bio-Rad Laboratories, Inc.’s own tally for this item (“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026”): 7,037,199 for, 38,994 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes …”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR
Largest asset managers voting on “Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,645,0010 00For
Capital Group764,0420 00For
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST388,1910 00For
Dimensional347,6670 00For
Fidelity309,6820 00For
MFS288,7100 00For
Investment Managers Series Trust III259,1060 00For
Parnassus253,2390 00For
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,8110 00For
John Hancock135,1450 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price80,7490 00For
Putnam80,5520 00For
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable47,1040 00For
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS38,2930 00For
Jackson National36,6550 00For
FRANKLIN VALUE INVESTORS TRUST34,7730 00For
TIAA26,3270 00For

Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).

Stockholder proposal regarding dual class capital structure

Official resultFund totals may overlapSHAREHOLDER RIGHTS AND DEFENSESReported outcome: Not approved

Proposed by: John Chevedden

Combines 4 wordings of this item as funds reported it.

21% Not approved · of votes cast

FOR 21%AGAINST
FOR: 1,469,297AGAINST: 5,459,554
Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: Stockholder proposal regarding dual class capital structure.

Bio-Rad Laboratories, Inc.’s own tally for this item (“5. The stockholder proposal regarding dual class capital structure”): 1,469,297 for, 5,459,554 against — failed, per its Form 8-K filed April 24, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The stockholder proposal regarding dual class capital structure was not approved since the proposal did not receive the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock”
Support: 21% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).

Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR
Largest asset managers voting on “Stockholder proposal regarding dual class capital structure.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
FIRST EAGLE FUNDS1,957,1810 00For
Vanguard1,627,41617,586 00For
Capital Group764,0420 00For
BlackRock748,9110 00For
ARIEL INVESTMENT TRUST0388,191 00Against
Dimensional347,6670 00For
Fidelity309,6820 00For
MFS288,7100 00For
Investment Managers Series Trust III0259,106 00Against
Parnassus253,2390 00For
LONGLEAF PARTNERS FUNDS TRUST185,8680 00For
Charles Schwab182,72289 00For
John Hancock135,1450 00For
Allspring94,4700 00For
PIMCO88,1860 00For
T. Rowe Price80,7490 00For
Putnam80,5520 00For
Transamerica65,6920 00For
TRUST FOR PROFESSIONAL MANAGERS64,9770 00For
Equitable27,10420,000 00Mixed
RBB Fund Trust46,7620 00For
BOSTON TRUST WALDEN FUNDS38,2930 00For
Jackson National34,2002,455 00Mixed
FRANKLIN VALUE INVESTORS TRUST34,7730 00For
TIAA26,3270 00For

Showing the 25 largest of 116 asset managers. All 116 are in the interactive database (link above).

Largest Bio-Rad Laboratories, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 26,958,000 shares outstanding at the time of that meeting.

Fund voting reports: top Bio-Rad Laboratories, Inc. shareholders by shares voted on “Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.”, 2025-2026
#Asset manager % of shares outstanding
1FIRST EAGLE FUNDS 7.26%
2Vanguard 6.10%
3Capital Group 2.83%
4BlackRock 2.78%
5ARIEL INVESTMENT TRUST 1.44%
6Dimensional 1.29%
7Fidelity 1.15%
8MFS 1.07%
9Investment Managers Series Trust III 0.96%
10Parnassus 0.94%
Institutional-manager reports: top Bio-Rad Laboratories, Inc. shareholders by shares voted on “Advisory vote to approve executive compensation.”, 2025-2026
#Asset manager % of shares outstanding
1First Eagle Investment Management, LLC 8.76%
2BlackRock 1.92%
3EARNEST PARTNERS LLC 1.83%
4MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 1.69%
5Capital Group 1.67%
6First Pacific Advisors, LP 1.49%
7State Street 1.48%
8UBS 1.27%
9GEODE CAPITAL MANAGEMENT, LLC 1.26%
10Capital Research Global Investors 1.16%

Reported Bio-Rad Laboratories, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Bio-Rad Laboratories, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group1,774,263 6.58%Form 13F, quarter ended March 31, 2026
BlackRock1,680,060 6.23%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors1,089,323 4.04%Form 13F, quarter ended March 31, 2026
State Street559,570 2.08%Form 13F, quarter ended March 31, 2026
Geode Capital364,682 1.35%Form 13F, quarter ended March 31, 2026
Northern Trust218,497 0.81%Form 13F, quarter ended March 31, 2026
Charles Schwab196,558 0.73%Form 13F, quarter ended March 31, 2026
Morgan Stanley186,387 0.69%Form 13F, quarter ended March 31, 2026
Franklin Templeton170,354 0.63%Form 13F, quarter ended March 31, 2026
Citadel Advisors150,269 0.56%Form 13F, quarter ended March 31, 2026

Percentages above are of 26,958,000 shares outstanding, as reported by Bio-Rad Laboratories, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Bio-Rad Laboratories, Inc.'s shareholder meeting held April 21, 2026, in the 2025-2026 proxy season, 456 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,975 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve executive compensation. — Bio-Rad Laboratories, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Bio-Rad Laboratories, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 24, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Bio-Rad Laboratories, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Bio-Rad Laboratories, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Bio-Rad Laboratories (BIO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/bio-rad-laboratories-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.